Carcinogenesis Advance Access published online on March 19, 2007
Carcinogenesis, doi:10.1093/carcin/bgm058
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EGFRvIII ESCAPES DOWNREGULATION DUE TO IMPAIRED INTERNALIZATION AND SORTING TO LYSOSOMES
1 Department of Cellular and Molecular Medicine, The Panum Building, University of Copenhagen, DK-2200 Copenhagen, Denmark
2 Department of Radiation Biology, Section 6321, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark
3 Department of Molecular Biology, University of Copenhagen, DK-2200 Copenhagen, Denmark
Corresponding author: Hans S Poulsen, Department of Radiation Biology, Section 6321, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark, Tel: +45 35 45 63 03; Fax: +45 35 45 63 01; E-mail: skovgaard{at}rh.dk
EGFRvIII is a mutant variant of the epidermal growth factor receptor (EGFR) found exclusively in various cancer types. EGFRvIII lacks a large part of the extracellular domain and is unable to bind ligands; however, the receptor is constitutively phosphorylated and able to activate downstream signaling pathways. Failure to attenuate signaling by receptor downregulation could be one of the major mechanisms by which EGFRvIII becomes oncogenic. Using a cell system expressing either EGFR or EGFRvIII with no expression of other EGFR family members and with endogenous levels of key degradation proteins, we have investigated the downregulation of EGFRvIII and compared it to that of EGFR. We show that, in contrast to EGFR, EGFRvIII is inefficiently degraded. EGFRvIII is internalized, but the internalization rate of the mutated receptor is significantly less than that of unstimulated EGFR. Moreover, internalized EGFRvIII is recycled rather than delivered to lysosomes. EGFRvIII binds the ubiquitin ligase c-Cbl via Grb2, whereas binding via phosphorylated tyrosine residue 1045 seems to be limited. Despite c-Cbl binding, the receptor fails to become effectively ubiquitinylated. Thus, our results suggest that the long lifetime of EGFRvIII is caused by inefficient internalization and impaired sorting to lysosomes due to lack of effective ubiquitinylation.
+ Authors have contributed equally to this work
Received October 10, 2006; revised March 2, 2007; accepted March 9, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Marcotte, L. Zhou, H. Kim, C. D. Roskelly, and W. J. Muller c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential Mol. Cell. Biol., November 1, 2009; 29(21): 5858 - 5871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Bax, N. Gaspar, S. E. Little, L. Marshall, L. Perryman, M. Regairaz, M. Viana-Pereira, R. Vuononvirta, S. Y. Sharp, J. S. Reis-Filho, et al. EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines Clin. Cancer Res., September 15, 2009; 15(18): 5753 - 5761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Huang, A. M. Xu, and F. M. White Oncogenic EGFR Signaling Networks in Glioma Sci. Signal., September 8, 2009; 2(87): re6 - re6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sulahian, O. Cleaver, and L. J.-s. Huang Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia Blood, May 21, 2009; 113(21): 5287 - 5297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Abella and M. Park Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E973 - E984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Chamberlain, T. Chan, J. C. Oberg, A. D. Hawrysh, K. M. James, A. Saxena, J. Xiang, and D. H. Anderson Disrupted RabGAP Function of the p85 Subunit of Phosphatidylinositol 3-Kinase Results in Cell Transformation J. Biol. Chem., June 6, 2008; 283(23): 15861 - 15868. [Abstract] [Full Text] [PDF]
|
|